MAP30 showed anti-tumor effects that attributed to reduce the expression levels of growth factor receptors such as the transmembrane tyrosine kinase receptor HER2 (also known as neu or c-erb-2), which has been implicated in breast cancer [10]. Here, ERBB2 is linked to neoplasm.